A5070264087- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Occupational and environmental lung diseases
- Pleural and Pulmonary Diseases
- Medical Imaging Techniques and Applications
- Lymphoma Diagnosis and Treatment
- Cytokine Signaling Pathways and Interactions
- Cancer Research and Treatments
- HER2/EGFR in Cancer Research
- Pancreatic and Hepatic Oncology Research
- Bladder and Urothelial Cancer Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Genetic factors in colorectal cancer
- Renal cell carcinoma treatment
- Radiomics and Machine Learning in Medical Imaging
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cancer Treatment and Pharmacology
- Neuroendocrine Tumor Research Advances
- Peptidase Inhibition and Analysis
- Advanced Radiotherapy Techniques
- Microbial Inactivation Methods
Intergroupe Francophone de Cancérologie Thoracique
2016-2025
Columbia University Irving Medical Center
2016
LBA8507 Background: To date, no treatment is recommended in MPM pts progressing after 1 st -line pemetrexed-platinum doublet. Disease control rate (DCR) <30% with all drugs tested 2 nd setting. Preliminary results suggested possible activity of anti-PD-1 mAb /3 rd- line, opposed to single agent anti-CTLA-4 mAb. Therefore anti-PD1 efficacy deserves confirmation, and + combination value currently unknown MPM. Methods: In this multicenter randomized non comparative phase trial, eligible had...
The purpose of this study was to assess the prognostic value <sup>18</sup>F-FDG PET parameter variation between baseline and 42 Gy (PET2) radiochemotherapy at 6 mo 1 y evaluation in patients with stage III inoperable nonsmall cell lung cancer based on RECIST 1.1. <b>Methods:</b> In total, 158 a prospective multicenter phase II/III were analyzed. Patients randomized into 2 groups: an experimental arm (group A) standard B). from group A residual metabolism PET2 A+) received radiation boost (74...
LBA8507 The full, final text of this abstract will be available at abstracts.asco.org 7:30 AM (EDT) on Monday, June 5, 2017, and in the Annual Meeting Proceedings online supplement to 20, issue Journal Clinical Oncology. Onsite Meeting, printed Monday edition ASCO Daily News.
Abstract Purpose: Double inhibition of epidermal growth factor receptor (EGFR) using a tyrosine kinase inhibitor plus monoclonal antibody may be novel treatment strategy for non–small cell lung cancer (NSCLC). We assessed the efficacy and toxicity afatinib + cetuximab versus alone in first-line advanced EGFR-mutant NSCLC. Patients Methods: In this phase II, randomized, open-label study, patients with stage III/IV EGFR-positive NSCLC were randomly assigned (1:1) to receive (group A) or A C)....
Background STK11/LKB1 mutations have been associated with primary resistance to PD-1 axis inhibitors and poor prognosis in advanced KRAS-mutant lung adenocarcinoma. This study aimed assess the prognostic significance of alterations localized non-squamous non-small cell carcinoma (non-sq NSCLC). Patients methods Surgical samples from patients undergoing complete resection for stage IIa, IIb, or IIIa (N2 excluded) non-sq NSCLC randomized adjuvant phase II trial (NCT00775385 IFCT-1801 TASTE...
Abstract Purpose: The incidence of lung cancer has dramatically increased in women. Preclinical data have suggested that combining EGFR–tyrosine kinase inhibitor (TKI) with an antiestrogen may overcome resistance to EGFR-TKI. Patients and Methods: IFCT-1003 LADIE trial was a 2 × arms parallel open-label randomized phase II trial. EGFR-TKI–naïve postmenopausal women advanced were treated gefitinib (G) versus + fulvestrant (G+F) the EGFR-mutated group (EGFR+) or erlotinib (E) (E+F) EGFR...
9097 Background: The incidence of lung cancer is increasing dramatically in women with recent findings as the preferential involvement EGFR pathway and potential impact hormonal factors women. Preclinical data have shown that combination an EGFR-TKI anti-estrogen could overcome resistance to EGFR-TKI. Methods: IFCT-1003 LADIE Trial was a 2x2 arms parallel open-label randomized phase II trial. PS 0-2 post-menopausal advanced stage adenocarcinoma were treated gefitinib (G 250 mg/day) vs. G +...
9079 Background: First-line treatment of metastatic EGFR-mutated NSCLC relies on EGFR-TKIs. However, all patients (pts) eventually develop progression. Dual inhibition EGFR with afatinib (A), an irreversible pan-erbB TKI, and cetuximab (C), monoclonal antibody, has shown activity in pts acquired resistance to TKIs, regardless the T790M status. Methods: We conducted a phase II randomized trial advanced harboring activating mutation, who had not received prior therapy. Pts were treated A (40...
TPS9144 Background: Second generation ALK tyrosine kinase inhibitors (ALK-TKI), including brigatinib, provide substantial therapeutic benefit in first-line treatment of ALK-positive NSCLC patients (pts) but relapse eventually occurs all pts due to development drug resistance, possibly caused by emergence drug-tolerant cells (DTC). Combining chemotherapy TKI may prevent DTC preclinical studies, and results prolonged progression-free survival (PFS) overall EGFR-mutant NSCLC. We hypothesize...
7510 Background: P is an anti-angiogenic agent approved in metastatic renal cell carcinoma and sarcoma. We have previously reported compliance of adjuvant (i.e. % patients (pts) able to receive at least 3 months (m.) P, whatever the dose) stage I NSCLC. Compliance has already been (WCLC 2013) found adequate dose 400 mg/d (69% [95%CI 50-84] (p = 0.027, compared 38% 800 mg/d) vs 93% 77-99] placebo. Here we report survival data. Methods: In this double-blind non-comparative randomized...
8526 Background: MRD aims to detect circulating biomarkers of micrometastatic disease and ultimately predict recurrences. The IFCT-0703 randomized phase II trial failed show a benefit 6 months adjuvant pazopanib (P) vs. placebo after resection stage I NSCLC (7th TNM edition). outcome pts based on their status has been evaluated. Methods: Blood samples were collected in EDTA tubes (Becton Dickinson Company) surgery (T0), 3 (T3) P or at the end treatment (T6). Plasmas obtained double...
A retrospective review was performed of patients with colorectal cancer metastasis to the liver not amenable alternative treatment options or ablation techniques undergoing percutaneous irreversible electroporation (IRE) assess for efficacy and outcomes. After IRB approval, clinical imaging data IRE at a single institution between 2009-2013 were evaluated analyzed. Twenty-nine 42 unique procedures 55 separate lesions included. Technical success occurred in 28 patients, one failure due...